The Cleveland Area Reliant IRB Review Process
The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.
What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.
The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.
For further information, contact Kim Volarcik at (216) 368-0134 or firstname.lastname@example.org.
Pilot Grants Available from CGREAL
The Center for Genetic Research Ethics and Law (CGREAL) is currently accepting applications for pilot projects from Case Western Reserve University and Cleveland Clinic faculty who are interested in developing research on:
These grants are designed to support exploratory efforts towards the development of larger scholarly projects or lines of research related to CGREAL’s mission to facilitate interdisciplinary inquiry into the ethical, legal, and social implications of new advances in genetic and genomic science.
- Ethical, legal, and social issues (ELSI) in the design and conduct of human genetic research, or
- The translation of research results into clinical medicine, public health, and health policy needs related to genetics.
Criteria for evaluation will focus on the potential for expanding and enriching the range of perspectives being brought to genetic research ethics and law at CGREAL. Preference will be given to projects that are deemed likely to foster further collaborative research opportunities.
Requests may be made for up to $5,000. Funds may not be used for faculty salary support. Applications are encouraged from Case Western University and Cleveland Clinic faculty at any rank/level.
Applications will be accepted on a rolling basis and funding for awarded seed grants will be available immediately upon project approval.
Interested faculty should contact Aaron Goldenberg (email@example.com or 216-368-8729).
For further information on the Center for Genetic Research Ethics and Law, see http://www.case.edu/med/bioethics/cgreal/
Case Comprehensive Cancer Center
All Faculty members are invited to submit concept proposals for 5 year Projects to compete for incorporation as a full project proposal in the upcoming GI SPORE competing renewal application that will be prepared starting in January 2015 for submission in September 2015 All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of human tissues.
Proposals must include two project leaders; one Basic Science leader and one Clinical leader. Maximum Funding Level – $185,000/year direct cost for 5 years ($925,000 total direct costs).
Completed proposals must be emailed to John Pounardjian, firstname.lastname@example.org. For more information on GI SPORE, visit the CaseCCC website.
Department of Defense
The Department of Defense has announced the following new funding opportunities:
Department of the Army - USAMRAA
DoD Orthotics and Prosthetics Outcomes Research Award
U.S. Army Medical Research and Materiel Command Broad Agency Announcement (BAA) for Extramural Medical Research - Dept. of the Army -- USAMRAA — W81XWH-BAA-15-1
Opening date: October 1, 2014
Closing date: September 30, 2015
Pre-Proposals:Applicants are encouraged to submit their Pre-Proposals as early as possible in the fiscal year as funding is based on availability
Invitation to Submit: within 120 days of pre-proposal submission
Full Proposals: submitted within 90 days of the invitation
Notice of Awards: within 180 days of submission
Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.
Programs of interest:
1. Military Infectious Diseases Research
2. Combat Casualty Care Research
3. Military Operational Medicine Research
4. Clinical and Rehabilitative Medicine Research
5. Medical Biological Defense Research
6. Medical Chemical Defense Research
7. Medical Training and Health Information Sciences
8. Radiation Health Effects Research
9. Special Investment Areas
Office of Strategic Initiatives (OSI): CWRU School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC.
Contact OSI: Irene Shaland - email@example.com - 216.368.4970.
New Policy from NIH to Balance Sex in Cell and Animal Studies
NIH announced last week a new policy requiring "a balance of male and female cells and animals in preclinical studies in all future applications." In this week's Nature, Janine Clayton and Francis Collins write, "The over-reliance on male animals and cells in preclinical research obscures key sex differences that could guide clinical studies. And it might be harmful: women experience higher rates of adverse drug reactions than men do. Furthermore, inadequate inclusion of female cells and animals in experiments and inadequate analysis of data by sex may well contribute to the troubling rise of irreproducibility in preclinical biomedical research."
Read more at: http://ow.ly/wSqy6.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
firstname.lastname@example.org no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be